Edesa Biotech Inc. (NASDAQ: EDSA) shares are 98.78% up in the year-to-date (YTD) period and have moved 40.28% or $2.34 higher in the latest trading session. However, stock’s trailing 12-month performance remains nearly +415.82% lower. Comparatively, the stock is -57.33% down YTD and 157.63% over the trailing 3-month period. If we look at the shorter duration, its week performance is 29.37% and -13.76% over the month.
0 of the 1 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 1 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $8.15. The forecasts give the Edesa Biotech Inc. stock a price target range of $16.00 on the higher side while at least one analyst think the stock could plunge to a low of $16.00. The two limits represent an upside potential of 49.06% or 49.06%.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 22 over the last 12 months, while SEC filings reveal that there have been 1 insider sales over the same period. Insiders have purchases 331,451 shares while those sold by company executives and officers stand at 1,809. The last 3 months have seen insiders trade a total of 0 and 0 in purchases and sales respectively.
Nijhawan Pardeep, a Chief Executive Officer at the company, bought 3,000 shares worth $8939.0 at $2.98 per share on May 26. The President had earlier bought another 2,500 EDSA shares valued at $7499.0 on May 27. The shares were bought at $3.00 per share. Nijhawan Pardeep (Chief Executive Officer) bought 5,000 shares at $1.87 per share on Mar 17 for a total of $9373.0 while Sistilli Carlo, (Director) bought 2,436 shares on Jan 08 for $10012.0 with each share fetching $4.11.
Qutoutiao Inc. (NASDAQ:QTT), on the other hand, is trading around $2.77 with a market cap of $838.31M and analyst research firms have a negative stance on its shares. Analysts predict that the stock will reach $4.19 and spell out a more modest performance – a 33.89% return. Some analysts are even forecasting -$0.39 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the Qutoutiao Inc. (QTT) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
QTT’s operating expenses over the recent quarter were at $208.64 million. This represented a -3.13% of the company’s total revenues which amounted $202.31 million. With this in place, we can see that the company’s diluted EPS declined -$0.27 on the year-over-year period, shrinking to -$0.10 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Jun 2020), the total assets figure advanced to $355.93 million from $422.33 million over the previous quarter. Short term investments amounted to $134.48 million while total current assets were at $311.02 million. The company’s free cash flow for the quarter was $0.0.
Investors are also buoyed by the number of investors in a company, with Qutoutiao Inc. having a total of 50 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 3.54 million shares worth more than $10.55 million. As of Jun 29, 2020, Vanguard Group, Inc. (The) held 2.25% of shares outstanding.
The other major institutional holder is Krane Funds Advisors LLC, with the investment firm holding over 1.48 million shares as of Jun 29, 2020. The firm’s total holdings are worth over $4.4 million and represent 0.94% of shares outstanding.